In adults, evidence from randomized controlled trials has matured. A 2024 systematic review and meta-analysis pooling 17 randomized MSC trials demonstrated significant improvements in left ventricular ejection fraction (LVEF), ventricular volumes, and functional capacity, with no new safety concerns. However, heterogeneity in cell source, dosing, and delivery route limits universal conclusions [2]. The strongest signals […]
